molmir Inc. (based in Nara, Japan, CEO: Eiichiro Mori, M.D., Ph.D.) is proud to announce that it has entered into an agreement with OrganoTherapeutics SARL (based in Esch-sur-Alzette, Luxembourg, CEO: Jens Schwamborn, Ph.D.) for R&D collaboration to develop novel therapies for Parkinson’s disease.
According to a 2020 Ministry of Health, Labor and Welfare survey, most people diagnosed with Parkinson’s disease are over 50 years old, approximately 250,000 Japanese are living with Parkinson’s disease. Due to rapidly aging in Japan, the number of people living with Parkinson’s disease is predicted to increase in the coming decades.
molmir’s core technologies, CHEmir (analytical chemistry) and MAGmir (solution nuclear magnetic resonance) can capture 3D structure and dynamics of molecules has been challenging until now. Currently, molmir implements these technologies to develop therapeutics for ALS (Amyotrophic Lateral Sclerosis), which is known as one of neurodegenerative diseases.
OrganoTherapeutics is at the forefront of developing patient-specific 3D midbrain organoids, providing a physiologically relevant platform for drug screening and disease modeling. Their technology enables the study of neurodegenerative diseases in a human context, facilitating the identification of effective therapeutic candidates.
This partnership seeks to expedite developing new treatments for Parkinson’s disease by integrating molmir’s advanced molecular sensing technologies and OrganoTherapeutics’ high- fidelity human-derived midbrain organoid models.
[OrganoTherapeutics SARL]
OrganoTherapeutics is an academic-spinout biotechstartup company, whose CEO is Jens Schwamborn, Ph.D., a Full Professor at the University of Luxembourg. They have the mission to accelerate the development of therapeutics against neurodegeneration. The current focus of OrganoTherapeutics is on Parkinson’s disease.
They are convinced that therapeutics targeting complex human diseases like Parkinson’s, need to be developed with complex human patient-specific models. Their team has developed Parkinson’s disease patient-specific cell culture models, organoids and assembloids, that replicate the Parkinson’s pathology and – to an extent – that cannot be found in any other cell culture or animal model.
For inquiries to OrganoTherapeutics, visit: https://www.organo-therapeutics.com/contact
[molmir, Inc,]
molmir is an academic-spinout biotech startup company certified by Nara Medical University, National Institute of Advanced Industrial Science and Technology (AIST), and Tokushima University. Their mission is to deliver new therapeutics to patients who currently have no treatment options, by creating a drug discovery ecosystem that brings together academic knowledge and research, including their core technologies CHEmir and MAGmir.
CEO of molmir, Eiichiro Mori, M.D, Ph.D., has assembled a unique team called TEAmir, consisting of 15 scientific advisors from 13 institutions, by leveraging his academic achievements and network. TEAmir collaborates with clinicians and researchers to address various challenges in the pharmaceutical process and propose strategies for drug development.
For further information, visit: https://www.molmir.co.jp/
